Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Sage Therapeutics, Inc. develops treatments for central nervous system disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Sage Therapeutics operates in the United States.
Website: sagerx.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (51.8%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -8.5% (LTM)
  • Share price is 81.6% higher than minimum and 85.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: SAGE
Share price, USD:  (0.0%)8.68
year average price 8.25  


year start price 7.14 2025-02-14

min close price 6.38 2025-05-14

max close price 9.30 2025-06-20

current price 8.68 2026-02-13
Common stocks: 59 912 378

Dividend Yield:  0.0%
EV / Sales: 4.7x
Margin (EBITDA LTM / Revenue): -637.4%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 520
Net Debt ($m): -56
EV (Enterprise Value): 464
EBITDA LTM (млн $): -631
Price to Book: 1.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-30zacks.com

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

2025-07-01globenewswire.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)

2025-06-18businesswire.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

2025-06-17zacks.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

2025-06-17zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

2025-06-16businesswire.com

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

2025-04-29seekingalpha.com

Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript

2025-04-20accessnewswire.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

2025-04-13accessnewswire.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

2025-03-30accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-07-30 2025-04-29 2024-10-29 2024-07-31 2024-04-25 2023-11-07 2023-08-07 2023-05-02 2022-11-08
acceptedDate 2025-07-30 16:20:54 2025-04-29 16:18:21 2025-02-11 16:14:58 2024-10-29 16:20:23 2024-07-31 16:15:30 2024-04-25 07:15:32 2024-02-14 07:20:39 2023-11-07 07:00:35 2023-08-07 07:20:50 2023-05-02 07:21:17 2023-02-16 07:31:44 2022-11-08 07:20:56 2022-02-24 07:22:43 2021-02-24 07:15:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 32M 14M 41M 12M 9M 8M 86M 3M 2M 3M 8M 2M 6M 1 114M
costOfRevenue -55 000 655 000 9M 5M 1M 1M 2M 905 000 205 000 230 000 813 000 184 000 553 000 565 000
grossProfit 32M 13M 32M 7M 7M 7M 84M 2M 2M 3M 7M 2M 6M 1 114M
grossProfitRatio 1.002 0.953 0.555 0.837 0.839 0.667 0.917 0.93 0.894
researchAndDevelopmentExpenses 24M 23M 226M 55M 63M 72M 356M 102M 97M 93M 326M 82M 283M 293M
generalAndAdministrativeExpenses 62M 0 216M 53M 56M 53M 275M 78M 75M 66M 228M 61M 183M 197M
sellingAndMarketingExpenses 0 0 0 0 0 -597 000 0 0 76 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 62M 58M 216M 53M 56M 52M 275M 78M 76M 66M 228M 61M 183M 197M
otherExpenses -230 000 513 000 22M 0 15 000 -12 000 33M -55 000 -41 000 -188 000 15 000 0 134 000 250 000
operatingExpenses 86M 81M 464M 108M 119M 124M 631M 180M 173M 159M 554M 143M 467M 490M
costAndExpenses 86M 82M 474M 113M 120M 125M 667M 181M 173M 159M 555M 143M 467M 490M
interestIncome 4M 5M 32M 8M 8M 9M 39M 10M 10M 9M 14M 4M 3M 10M
interestExpense 0 0 0 0 0 0 0 0 0 -9M 0 4M 0 0
depreciationAndAmortization 104 000 112 000 1M 255 000 311 000 336 000 1M 330 000 331 000 323 000 1M 278 000 4M 3M
ebitda -54M -67M -409M -101M -111M -117M -545M -144M -170M -155M -546M -133M -457M 627M
ebitdaratio -1.709 -4.797 -8.525 -12.825 -14.774 -53.137 -68.899 -47.198 -76.434
operatingIncome -54M -67M -432M -101M -111M -117M -580M -212M -170M -155M -547M -141M -461M 596M
operatingIncomeRatio -1.705 -4.797 -8.525 -12.861 -14.816 -78 -68.899 -47.198 -81.357
totalOtherIncomeExpensesNet 4M 5M 32M 8M 8M 9M 38M -34M -41 000 9M 14M 4M 3M 10M
incomeBeforeTax -50M -62M -401M -94M -103M -108M -541M -202M -160M -147M -533M -137M -458M 606M
incomeBeforeTaxRatio -1.568 -4.424 -7.881 -11.885 -13.729 -74.238 -64.804 -44.574 -78.967
incomeTaxExpense 0 0 0 0 0 292 724 0 23M -11M -9M 0 0 0 0
netIncome -50M -62M -401M -94M -103M -108M -541M -202M -160M -138M -503M -137M -451M 606M
netIncomeRatio -1.568 -4.424 -7.881 -11.885 -13.729 -74.238 -64.804 -41.951 -78.967
eps -0.79 -1.01 -6.59 -1.53 -1.7 -1.8 -9.05 -3.37 -2.68 -2.32 -8.49 -2.31 -7.68 11.66
epsdiluted -0.79 -1.01 -1.53 -1.7 -1.8 -3.37 -2.68 -2.32 -2.31
weightedAverageShsOut 63M 62M 61M 61M 61M 60M 60M 60M 60M 60M 59M 59M 59M 52M
weightedAverageShsOutDil 63M 62M 61M 61M 61M 60M 60M 60M 60M 60M 59M 59M 59M 53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-14 2023-02-16 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 32M 39M 14M 3M 10M
ebit -411M -546M -547M -461M 624M
nonOperatingIncomeExcludingInterest -22M -33M 0 0 -28M
netIncomeFromContinuingOperations -401M -541M -533M -458M 606M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -401M -541M -533M -458M 606M
epsDiluted -6.59 -9.05 -8.49 -7.68 11.43

Balance Sheet Statement

Property 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-07-30 2025-04-29 2024-10-29 2024-07-31 2024-04-25 2023-11-07 2023-08-07 2023-05-02 2022-11-08
acceptedDate 2025-07-30 16:20:54 2025-04-29 16:18:21 2025-02-11 16:14:58 2024-10-29 16:20:23 2024-07-31 16:15:30 2024-04-25 07:15:32 2024-02-14 07:20:39 2023-11-07 07:00:35 2023-08-07 07:20:50 2023-05-02 07:21:17 2023-02-16 07:31:44 2022-11-08 07:20:56 2022-02-24 07:22:43 2021-02-24 07:15:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 67M 45M 81M 100M 101M 174M 71M 149M 121M 207M 163M 200M 294M 1 661M
shortTermInvestments 298M 379M 423M 470M 547M 544M 682M 727M 881M 923M 1 110M 1 194M 1 448M 438M
cashAndShortTermInvestments 366M 424M 504M 569M 648M 718M 753M 876M 1 003M 1 130M 1 272M 1 394M 1 742M 2 101M
netReceivables 27M 11M 9M 15M 0 14M 83M 23M 15M 15M 14M 18M 19M 0
inventory 0 0 0 0 0 1 0 1 -61M -15M -64M 0 0 0
otherCurrentAssets 17M 20M 18M 21M 40M 23M 33M 35M 46M 74M 51M 53M 0 23M
totalCurrentAssets 409M 454M 531M 605M 687M 755M 869M 933M 1 003M 1 203M 1 272M 1 465M 1 801M 2 122M
propertyPlantEquipmentNet 11M 11M 12M 12M 2M 4M 6M 8M 10M 12M 13M 15M 19M 32M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 1M 0 0 0 0 2M 0 1M 0 0 1M 0 1M 2M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 2M 4M 4M 5M 8M 6M 7M 7M 70M 6M 69M 6M 4M 3M
totalNonCurrentAssets 14M 15M 16M 17M 10M 12M 13M 16M 80M 17M 84M 21M 25M 37M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 423M 470M 547M 622M 697M 768M 882M 950M 1 082M 1 221M 1 356M 1 486M 1 825M 2 159M
accountPayables 692 000 5M 13M 7M 9M 6M 10M 11M 9M 12M 19M 7M 10M 4M
shortTermDebt 2M 2M 0 166 000 3M 3M 0 7M 8M 8M 8M 8M 7M 9M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 42M 43M 15M 53M 58M 52M 21M 115M 80M 65M 36M 85M 41M 32M
totalCurrentLiabilities 45M 50M 72M 60M 69M 62M 83M 133M 97M 85M 99M 100M 85M 67M
longTermDebt 10M 10M 0 10M 0 0 0 0 1M 3M 4M 6M 11M 19M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 102 000 102 000 -4M 100 000 -11M -19M
totalNonCurrentLiabilities 10M 10M 11M 10M 0 0 0 0 1M 3M 5M 6M 11M 20M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 10M 12M 12M 10M 1M 3M 5M 7M 9M 10M 12M 14M 18M 28M
totalLiabilities 54M 60M 82M 71M 69M 62M 83M 133M 98M 88M 104M 106M 96M 87M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 6000 6000 6000 6000 6000 6000 6000 6000 6000 6000 6000 6000 6000 6000
retainedEarnings -3 082M -3 033M -2 970M -2 875M -2 781M -2 678M -2 570M -2 537M -2 335M -2 175M -2 028M -1 881M -1 495M -1 037M
accumulatedOtherComprehensiveIncomeLoss 15 000 142 000 244 000 901 000 -691 000 -787 000 -814 000 -4M -6M -5M -10M -15M -3M 415 000
othertotalStockholdersEquity 3 451M 3 442M 3 425M 3 410M 3 385M 3 357M 3 325M 3 313M 3 276M
totalStockholdersEquity 369M 410M 465M 552M 628M 706M 800M 817M 984M 1 133M 1 253M 1 380M 1 729M 2 072M
totalEquity 369M 410M 465M 552M 628M 706M 800M 817M 984M 1 133M 1 253M 1 380M 1 729M 2 072M
totalLiabilitiesAndStockholdersEquity 423M 470M 622M 697M 768M 950M 1 082M 1 221M 1 486M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 423M 470M 547M 622M 697M 768M 882M 950M 1 082M 1 221M 1 356M 1 486M 1 825M 2 159M
totalInvestments 300M 379M 423M 470M 547M 546M 682M 727M 881M 923M 1 110M 0 1 448M 438M
totalDebt 11M 12M 12M 10M 1M 3M 5M 7M 9M 10M 12M 14M 18M 28M
netDebt -56M -33M -69M -89M -100M -171M -66M -142M -113M -196M -151M -186M -276M -1 633M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-14 2023-02-16 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 9M 83M 0 0 0
otherReceivables 0 0 14M 19M 0
prepaids 0 0 0 40M 0
totalPayables 13M 10M 19M 10M 4M
otherPayables 0 0 0 0 0
accruedExpenses 43M 46M 29M 19M 15M
capitalLeaseObligationsCurrent 1M 5M 8M 7M 9M
capitalLeaseObligationsNonCurrent 11M 0 4M 11M 19M
treasuryStock -400 000 -400 000 -400 000 -400 000 -400 000
additionalPaidInCapital 3 436M 3 370M 3 291M 3 227M 3 110M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE SAGE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-07-30 2025-04-29 2024-10-29 2024-07-31 2024-04-25 2023-11-07 2023-08-07 2023-05-02 2022-11-08
acceptedDate 2025-07-30 16:20:54 2025-04-29 16:18:21 2025-02-11 16:14:58 2024-10-29 16:20:23 2024-07-31 16:15:30 2024-04-25 07:15:32 2024-02-14 07:20:39 2023-11-07 07:00:35 2023-08-07 07:20:50 2023-05-02 07:21:17 2023-02-16 07:31:44 2022-11-08 07:20:56 2022-02-24 07:22:43 2021-02-24 07:15:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -50M -62M -401M -94M -103M -108M -541M -202M -160M -147M -533M -137M -458M 606M
depreciationAndAmortization -442 000 -981 000 -5M 255 000 311 000 336 000 1M 330 000 331 000 323 000 1M 278 000 4M 3M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 9M 7M 55M 14M 17M 14M 73M 29M 12M 20M 62M 13M 105M 96M
changeInWorkingCapital 25M -25M 85M -1M 7M 58M -67M 42M 21M -24M 6M 4M -19M -40M
accountsReceivables 0 0 74M -5M 566 000 73M 0 -7M 0 0 5M 0 -19M 0
inventory 0 0 0 0 0 0 0 7M 0 0 -5M 0 19M 0
accountsPayables -5M -7M 2M -2M 2M -4M -8M 2M -3M -7M 8M 2M 7M -12M
otherWorkingCapital 18M -18M 9M 5M 4M -10M -59M 40M 24M 7M -3M 0 -7M -28M
otherNonCashItems -43M -25 000 -344 000 -2M 13M -56M -6M -5M -4M -3M 4M 1M -11M -688 000
netCashProvidedByOperatingActivities -59M -82M -267M -82M -80M -38M -541M -136M -132M -154M -460M -119M -378M 664M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 -553 000 -328 000 -112 000 -225 000 -937 000 -364 000 -372 000 -345 000
acquisitionsNet 0 0 0 0 0 0 0 -161M 0 0 -326M 0 1 002M -443M
purchasesOfInvestments -69M -88M -451M -102M -198M -62M -595M -70M -233M -157M -881M -251M -1 990M -459M
salesMaturitiesOfInvestments 150M 134M 718M 183M 198M 201M 1 038M 231M 278M 352M 1 207M 363M 988M 902M
otherInvestingActivites 0 0 0 -386 000 139M 161M 0 0 0
netCashUsedForInvestingActivites 81M 46M 81M -386 000 139M 160M 46M 195M 111M
debtRepayment 0 0 0 0 0 -3M 0 0 0
commonStockIssued 0 0 1000 8M 2M 3M 0 0 0
commonStockRepurchased 0 0 0 3000 -1000 -2000 -903 000 -4000 0 0 -43 000 0 -1M 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -65 000 148 000 1M 8M -2000 10M 847 000 3M 1M
netCashUsedProvidedByFinancingActivities -65 000 148 000 1M 8M 2M 3M 847 000 3M 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 22M -36M 10M 1M -73M 102M -92M 27M -85M 44M -132M -7M -1 367M 1 534M
cashAtEndOfPeriod 69M 47M 82M 102M 101M 174M 72M 150M 123M 208M 164M 201M 296M 1 663M
cashAtBeginningOfPeriod 47M 82M 72M 101M 174M 72M 164M 123M 208M 164M 296M 208M 1 663M 129M
operatingCashFlow -59M -82M -267M -82M -80M -38M -541M -136M -132M -154M -460M -119M -378M 664M
capitalExpenditure 0 0 0 0 0 0 -553 000 -328 000 -112 000 -225 000 -937 000 -364 000 -372 000 -345 000
freeCashFlow -59M -82M -267M -82M -80M -38M -541M -136M -132M -154M -461M -119M -379M 664M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-14 2023-02-16 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 326M -1 002M 443M
netCashProvidedByInvestingActivities 267M 443M 325M -1 002M 443M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 8M 0 0 0 418M
netCommonStockIssuance 8M 0 0 0 418M
commonStockIssuance 8M 7M 3M 15M 418M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 2M 6M 3M 13M 9M
netCashProvidedByFinancingActivities 11M 6M 3M 13M 427M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-11 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-07-30 20:20 ET
Sage Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 20:09 ET
Sage Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 20:09 ET
Sage Therapeutics reported for 2025 q2
SEC form 8
2025-06-16 11:55 ET
Sage Therapeutics published news for 2025 q1
SEC form 8
2025-06-16 11:55 ET
Sage Therapeutics published news for 2025 q1
SEC form 8
2025-06-16 11:55 ET
Sage Therapeutics published news for 2025 q1
SEC form 10
2025-04-29 20:18 ET
Sage Therapeutics reported for 2025 q1
SEC form 10
2025-04-29 00:00 ET
Sage Therapeutics reported for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Sage Therapeutics published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Sage Therapeutics reported for 2025 q1
SEC form 10
2025-02-11 21:14 ET
Sage Therapeutics reported for 2024 q4
SEC form 10
2025-02-11 00:00 ET
Sage Therapeutics reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Sage Therapeutics published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Sage Therapeutics reported for 2024 q4
SEC form 8
2025-01-27 14:28 ET
Sage Therapeutics published news for 2024 q4
SEC form 8
2025-01-27 14:28 ET
Sage Therapeutics published news for 2024 q4
SEC form 10
2024-10-29 16:20 ET
Sage Therapeutics reported for 2024 q3
SEC form 8
2024-10-29 16:10 ET
Sage Therapeutics published news for 2024 q3
SEC form 8
2024-10-29 16:10 ET
Sage Therapeutics reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
Sage Therapeutics reported for 2024 q3
SEC form 10
2024-07-31 16:15 ET
Sage Therapeutics reported for 2024 q2
SEC form 8
2024-07-31 16:10 ET
Sage Therapeutics published news for 2024 q2
SEC form 8
2024-07-31 16:10 ET
Sage Therapeutics reported for 2024 q2
SEC form 10
2024-07-31 00:00 ET
Sage Therapeutics reported for 2024 q2
SEC form 10
2024-04-25 07:15 ET
Sage Therapeutics reported for 2024 q1
SEC form 8
2024-04-25 06:46 ET
Sage Therapeutics published news for 2024 q1
SEC form 8
2024-04-25 06:46 ET
Sage Therapeutics reported for 2024 q1
SEC form 10
2024-04-25 00:00 ET
Sage Therapeutics reported for 2024 q1
SEC form 10
2024-02-14 00:00 ET
Sage Therapeutics reported for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Sage Therapeutics published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Sage Therapeutics reported for 2023 q4
SEC form 10
2023-11-07 07:00 ET
Sage Therapeutics reported for 2023 q3
SEC form 8
2023-11-07 06:46 ET
Sage Therapeutics reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Sage Therapeutics published news for 2023 q3
SEC form 10
2023-08-07 07:20 ET
Sage Therapeutics reported for 2023 q2
SEC form 6
2023-08-07 06:45 ET
Sage Therapeutics reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Sage Therapeutics published news for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Sage Therapeutics published news for 2023 q2
SEC form 6
2023-06-16 16:06 ET
Sage Therapeutics published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Sage Therapeutics published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Sage Therapeutics reported for 2023 q1
SEC form 6
2023-03-16 06:37 ET
Sage Therapeutics published news for 2022 q4
SEC form 10
2023-02-16 07:31 ET
Sage Therapeutics reported for 2022 q4
SEC form 6
2023-02-16 06:45 ET
Sage Therapeutics published news for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Sage Therapeutics reported for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Sage Therapeutics reported for 2022 q4
SEC form 6
2023-02-06 06:45 ET
Sage Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 06:09 ET
Sage Therapeutics published news for 2022 q4
SEC form 6
2022-12-06 06:51 ET
Sage Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 07:20 ET
Sage Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 06:45 ET
Sage Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Sage Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Sage Therapeutics reported for 2022 q3
SEC form 10
2022-08-02 07:20 ET
Sage Therapeutics reported for 2022 q2
SEC form 6
2022-08-02 06:45 ET
Sage Therapeutics published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Sage Therapeutics reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Sage Therapeutics reported for 2022 q2
SEC form 6
2022-07-14 16:08 ET
Sage Therapeutics published news for 2022 q2
SEC form 6
2022-06-21 16:41 ET
Sage Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 07:01 ET
Sage Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 07:16 ET
Sage Therapeutics published news for 2022 q1
SEC form 10
2022-05-03 07:20 ET
Sage Therapeutics reported for 2022 q1
SEC form 6
2022-05-03 06:45 ET
Sage Therapeutics published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Sage Therapeutics reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Sage Therapeutics reported for 2022 q1
SEC form 6
2022-04-28 16:25 ET
Sage Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 07:22 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 06:45 ET
Sage Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Sage Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2022-02-16 07:00 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 07:31 ET
Sage Therapeutics published news for 2021 q4
SEC form 6
2021-12-01 07:00 ET
Sage Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 07:30 ET
Sage Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 07:22 ET
Sage Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Sage Therapeutics published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Sage Therapeutics published news for 2021 q3
SEC form 6
2021-10-19 08:01 ET
Sage Therapeutics published news for 2021 q3
SEC form 10
2021-08-03 07:20 ET
Sage Therapeutics published news for 2021 q2
SEC form 6
2021-08-03 07:01 ET
Sage Therapeutics published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Sage Therapeutics published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Sage Therapeutics published news for 2021 q2
SEC form 6
2021-06-15 06:50 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-06-10 16:05 ET
Sage Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 07:20 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-05-04 07:14 ET
Sage Therapeutics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Sage Therapeutics published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-04-12 07:17 ET
Sage Therapeutics published news for 2021 q1
SEC form 6
2021-03-18 06:55 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2021-03-17 08:04 ET
Sage Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 07:15 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 06:46 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2021-01-07 16:14 ET
Sage Therapeutics published news for 2020 q4
SEC form 6
2020-12-31 16:05 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-12-16 07:00 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-11-27 07:38 ET
Sage Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 07:15 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 07:00 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-10-15 09:14 ET
Sage Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 16:05 ET
Sage Therapeutics published news for 2020 q3